.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Novartis
Chubb
Moodys
Chinese Patent Office
US Department of Justice
QuintilesIMS
Healthtrust
Medtronic
Farmers Insurance

Generated: June 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,034,054

« Back to Dashboard

Claims for Patent: 6,034,054

Title: Stable insulin formulations
Abstract:The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Inventor(s): DeFelippis; Michael Rosario (Indianapolis, IN), Dobbins; Michael Allen (Lebanon, IN), Frank; Bruce Hill (Indianapolis, IN), Li; Shun (Indianapolis, IN), Rebhun; Dawn Marie (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/096,247
Patent Claims: 1. A solution formulation comprising: a physiologically tolerated buffer selected from the group consisting of TRIS and arginine; a monomeric insulin analog wherein the insulin analog is Lys.sup.B28 Pro.sup.B29 -human insulin; zinc; and a phenolic preservative.

2. The formulation of claim 1, wherein the buffer is TRIS.

3. The formulation of claim 2, further comprising an isotonicity agent and wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22.degree. C.

4. The formulation of claim 3, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 1.2 mg/mL and about 50 mg/mL.

5. The formulation of claim 4, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 3.0 mg/mL and about 35 mg/mL.

6. The formulation of claim 5, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 3.5 mg/mL and about 35 mg/mL.

7. The formulation of claim 6, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 7 mg/mL and about 35 mg/mL.

8. The formulation of claim 7, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 14 mg/mL and about 35 mg/mL.

9. The formulation of claim 8, wherein the concentration of Lys.sup.B28 Pro.sup.B29 -human insulin is between about 17.5 mg/mL and about 35 mg/mL.

10. The formulation of claim 6, wherein the phenolic preservative is a mixture of m-cresol and phenol.

11. The formulation of claim 10, wherein TRIS is present at a concentration of about 2 mg/mL; glycerol is the isotonicity agent and is present at a concentration of about 16 mg/mL; and wherein m-cresol is present at a concentration of about 1.76 mg/mL and phenol is present at a concentration of about 0.715 mg/mL.

12. A stable, soluble formulation of a monomeric insulin analog, for use in a continuous infusion system, consisting essentially of: an isotonicity agent; a buffer selected from the group consisting of TRIS and arginine; Lys.sup.B28 Pro.sup.B29 -human insulin; zinc; and a phenolic preservative.

13. The formulation of claim 1, which further comprises protamine.

14. A method for treating diabetes comprising administering an effective dose of the formulation of claim 1 to a patient in need thereof.

15. The method of claim 14, wherein the formulation is administered using a continuous infusion system.

16. A method for treating hyperglycemia comprising administering an effective dose of the formulation of claim 1 to a patient in need thereof.

17. The method of claim 16, wherein the formulation is administered using a continuous infusion system.

18. A method for treating diabetes comprising administering an effective dose of the formulation of claim 13 to a patient in need thereof.

19. A method for treating hyperglycemia comprising administering an effective dose of the formulation of claim 13 to a patient in need thereof .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Julphar
Colorcon
Argus Health
Deloitte
Citi
Medtronic
Healthtrust
Teva
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot